GERMANY – Selfapy, a Berlin, Germany-based digital health company, closed a €7m financing round.
The round was led by Medice Arzneimittel, a family-owned pharmaceutical company focused on the treatment of ADHD, with participation from existing investors healthcare-investor SHS, Think.Health Ventures, IBB Ventures and HTGF. The company intends to use the funds to develop further digital therapeutics for various mental health disorders, to grow in the German market, and to enter new European markets. Led by Co-CEOs Nora Blum, and Adham Kassab, Selfapy offers effective digital therapeutics for people with mental illnesses. The company’s online courses, which are based on the methods of cognitive behavioral therapy, reduce the symptoms of people with depression and generalized anxiety disorders. Just recently, Selfapy added two new online courses for people with binge-eating disorder and bulimia
nervosa to its portfolio, making it the first reimbursed digital therapeutics (DiGA) provider for eating disorders in Germany. 24/02/2023
nervosa to its portfolio, making it the first reimbursed digital therapeutics (DiGA) provider for eating disorders in Germany. 24/02/2023
